TABLE 3.

Univariate Analyses of Risk Factors for Death Among Neonates With HSV Infection

Characteristic	Unadjusted OR (95% CI)	P
Age categorya
0–7 d	Reference
8–14 d	0.76 (0.46–1.25)	.277
15–21 d	0.31 (0.14–0.67)	.003
22–28 d	0.07 (0.01–0.50)	.008
Male	0.98 (0.62–1.55)	.917
Race
Non-Hispanic white	Reference
Non-Hispanic black	1.06 (0.59–1.92)	.842
Hispanic	0.64 (0.28–1.47)	.298
Other	1.41 (0.73–2.72)	.312
Congenital anomaly	2.10 (1.20–3.67)	.009
Government payer	2.37 (1.40–4.03)	.001
HSV without complications	0.58 (0.28–1.18)	.133
Initial management
Delayed acyclovir therapy	1.50 (0.92–2.47)	.107
Skin testing for HSV	0.51 (0.27–0.99)	.048
Vasoactive agent infusions	27.42 (15.25–49.32)	<.001
Anticonvulsant therapy	2.89 (1.69–4.94)	<.001
Blood product transfusion	25.04 (14.16–44.29)	<.001
Endotracheal intubation	7.70 (4.39–13.49)	<.001

^aAge at hospital admission.